Q3 2024 Vaishali Pharma Ltd Earnings Call Transcript
Key Points
- Vaishali Pharma Ltd (NSE:VAISHALI) reported a strong financial performance in Q3 FY24 with total income rising to INR28.37 crores and an EBITDA margin of 12.05%.
- The company has a diversified product portfolio including APIs, formulations, surgical products, veterinary supplements, herbal items, nutraceuticals, and oncology products.
- Vaishali Pharma Ltd (NSE:VAISHALI) has a global presence with strategic partnerships in the Democratic Republic of Congo, Kenya, and Russia.
- The company introduced a new brand, Healthy, and launched innovative products like Healthy Biotin and Multivitamin Gummies.
- Vaishali Pharma Ltd (NSE:VAISHALI) aims to achieve INR500 crores in revenue with an EBITDA margin of 25% within the next five years.
- The company's margins have been historically volatile due to the varying performance of different business segments like APIs and formulations.
- Vaishali Pharma Ltd (NSE:VAISHALI) does not own its manufacturing units and relies on third-party manufacturing at 22 different sites, which may pose risks related to quality control and supply chain management.
- The company faces challenges in securing large international orders due to lengthy paperwork and regulatory requirements.
- The EBITDA margin for the nine months of FY24 was 16%, indicating room for improvement compared to the quarterly margin of 12%.
- Vaishali Pharma Ltd (NSE:VAISHALI) has a working capital cycle of 90 days, which may impact liquidity and operational efficiency.
Ladies and gentlemen, good day and welcome to Q3-FY24 result conference call of Vaishali Pharma Limited hosted by Kirin Advisors. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Ms. Vaishnavi Ambokar from Kirin Advisors. Thank you, and over to you, ma'am.
Thank you. On behalf of Kirin Advisors, I welcome you all to the conference call of Vaishali Pharma Limited. From the management side, we have Mr. Atul Vasani, Chairman and Managing Director; Mr. Dewansh Vasani, Executive Director; Mr. Ratnesh Singh, Chief Financial Officer.
Now, I hand over the call to Mr. Dewansh Vasani. Over to you, sir.
Good afternoon, and thank you for that warm welcome. I appreciate the opportunity to address the distinguished participants of this conference call. As we gather to discuss the performance of Vaishali Pharma Limited during the quarter
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |